NEW YORK, Aug. 10, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan, Inc. (NYSE:AGN) from February 25, 2014 through April 21, 2014, inclusive (the “Class Period”) of the important August 29, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Allergan investors under the federal securities laws.
To join the Allergan class action, go to http://rosenlegal.com/cases-1156.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The class action asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 arising from the 2014 attempted acquisition of Allergan by Valeant and its affiliates. The complaint alleges that certain Defendants traded on material non-public information regarding the proposed acquisition, and as a result, Class members that sold Allergan call options, purchased Allergan put options and/or sold Allergan equity forward contracts during the Class Period did so at prices that did not reflect the material nonpublic information known to Defendants. In this action, Plaintiff seeks an award of damages, and prejudgment interest, to Plaintiff and other Class members.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1156.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Instagram Outage Disrupts Thousands of U.S. Users
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



